OBJECTIVE: To assess whether the clinical course of HIV infection has changed from 1985 to 1995. DESIGN: Cohort Study. SETTING: Infectious disease clinic. SUBJECTS: 285 patients recruited from September 1985 to January 1995 with < or = 12 months between the dates of their last seronegative and first seropositive test result and with first follow up visit in the six months after seroconversion and at least 12 months' follow up. Patients were grouped according to the date of seroconversion. MAIN OUTCOME MEASURES: Time to CD4 cell count of < 500, 400, and 200 x 10(6) cells/l, and clinical outcome defining AIDS; variation in cell count per day between consecutive visits, and ratio between this variation and time from estimated date of seroconversion at each visit. RESULTS: The groups were similar in age, number with acute primary HIV infection, CD4 cell count at intake, and cell count at the beginning of antiretroviral treatment; they differed in sex ratio, risk factors for HIV, probability of CD4 cell decline to < 500, 400, and 200 x 10(6) cells/l. and risk of developing AIDS. Acute infection, seroconversion after December 1989, and serum beta 2 microglobulin > 296 nmol/l were independent predictors of poor clinical course. The speed of CD4 cell decline, expressed as cell variation divided by the number of days between consecutive visits, increased with more recent seroconversion (P = 0.02). Ratio between the speed of CD4 cell decline and time from estimated date of seroconversion at each visit was also higher in the patients who seroconverted after December 1989. CONCLUSIONS: The faster disease progression and the higher speed of CD4 cell decline at early stages in the patients with recently acquired HIV infection suggest changes in the clinical course of HIV infection.
OBJECTIVE: To assess whether the clinical course of HIV infection has changed from 1985 to 1995. DESIGN: Cohort Study. SETTING: Infectious disease clinic. SUBJECTS: 285 patients recruited from September 1985 to January 1995 with < or = 12 months between the dates of their last seronegative and first seropositive test result and with first follow up visit in the six months after seroconversion and at least 12 months' follow up. Patients were grouped according to the date of seroconversion. MAIN OUTCOME MEASURES: Time to CD4 cell count of < 500, 400, and 200 x 10(6) cells/l, and clinical outcome defining AIDS; variation in cell count per day between consecutive visits, and ratio between this variation and time from estimated date of seroconversion at each visit. RESULTS: The groups were similar in age, number with acute primary HIV infection, CD4 cell count at intake, and cell count at the beginning of antiretroviral treatment; they differed in sex ratio, risk factors for HIV, probability of CD4 cell decline to < 500, 400, and 200 x 10(6) cells/l. and risk of developing AIDS. Acute infection, seroconversion after December 1989, and serum beta 2 microglobulin > 296 nmol/l were independent predictors of poor clinical course. The speed of CD4 cell decline, expressed as cell variation divided by the number of days between consecutive visits, increased with more recent seroconversion (P = 0.02). Ratio between the speed of CD4 cell decline and time from estimated date of seroconversion at each visit was also higher in the patients who seroconverted after December 1989. CONCLUSIONS: The faster disease progression and the higher speed of CD4 cell decline at early stages in the patients with recently acquired HIV infection suggest changes in the clinical course of HIV infection.
Authors: Joshua T Herbeck; Viktor Müller; Brandon S Maust; Bruno Ledergerber; Carlo Torti; Simona Di Giambenedetto; Luuk Gras; Huldrych F Günthard; Lisa P Jacobson; James I Mullins; Geoffrey S Gottlieb Journal: AIDS Date: 2012-01-14 Impact factor: 4.177
Authors: Samuel Alizon; Viktor von Wyl; Tanja Stadler; Roger D Kouyos; Sabine Yerly; Bernard Hirschel; Jürg Böni; Cyril Shah; Thomas Klimkait; Hansjakob Furrer; Andri Rauch; Pietro L Vernazza; Enos Bernasconi; Manuel Battegay; Philippe Bürgisser; Amalio Telenti; Huldrych F Günthard; Sebastian Bonhoeffer Journal: PLoS Pathog Date: 2010-09-30 Impact factor: 6.823
Authors: Nancy Crum-Cianflone; Lynn Eberly; Yafeng Zhang; Anuradha Ganesan; Amy Weintrob; Vincent Marconi; R Vincent Barthel; Susan Fraser; Brian K Agan; Scott Wegner Journal: Clin Infect Dis Date: 2009-05-01 Impact factor: 9.079
Authors: Emma Hodcroft; Jarrod D Hadfield; Esther Fearnhill; Andrew Phillips; David Dunn; Siobhan O'Shea; Deenan Pillay; Andrew J Leigh Brown Journal: PLoS Pathog Date: 2014-05-01 Impact factor: 6.823
Authors: Viktor Müller; Franco Maggiolo; Fredy Suter; Nicoletta Ladisa; Andrea De Luca; Andrea Antinori; Laura Sighinolfi; Eugenia Quiros-Roldan; Giampiero Carosi; Carlo Torti Journal: PLoS Pathog Date: 2009-05-29 Impact factor: 6.823
Authors: Joshua T Herbeck; Geoffrey S Gottlieb; Xiuhong Li; Zheng Hu; Roger Detels; John Phair; Charles Rinaldo; Lisa P Jacobson; Joseph B Margolick; James I Mullins Journal: PLoS One Date: 2008-02-06 Impact factor: 3.240